Literature DB >> 2147233

Interleukin-1 receptor antagonist reduces mortality from endotoxin shock.

K Ohlsson1, P Björk, M Bergenfeldt, R Hageman, R C Thompson.   

Abstract

About five out of 1,000 patients admitted to hospital develop bacterial sepsis leading to shock, the mortality rate for which is high despite antibiotic therapy. The infection results in hypotension and poor tissue perfusion, and eventually leads to the failure of several organ systems. Bacterial endotoxin is thought to be the direct cause of shock in Gram-negative sepsis, because it can cause shock in animals, and antibodies against endotoxin prevent Gram-negative shock in animals and in humans. But, the symptoms of septic shock are the result of the actions of host cytokines induced by the endotoxin. The cytokine interleukin-1 has been implicated as an important mediator of septic shock because it can induce tachycardia and hypotension and act synergistically with tumour necrosis factor to cause tissue damage and death. We now report that a specific interleukin-1 receptor antagonist reduces the lethality of endotoxin-induced shock in rabbits, indicating that interleukin-1 does indeed play an important part in endotoxin shock.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2147233     DOI: 10.1038/348550a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  169 in total

1.  The tyrosine kinase inhibitor tyrphostin AG126 reduces the development of acute and chronic inflammation.

Authors:  S Cuzzocrea; M C McDonald; E Mazzon; D Siriwardena; G Calabrò; D Britti; G Mazzullo; A De Sarro; A P Caputi; C Thiemermann
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

2.  Hematopoietic stem-progenitor cells restore immunoreactivity and improve survival in late sepsis.

Authors:  Laura Brudecki; Donald A Ferguson; Deling Yin; Gene D Lesage; Charles E McCall; Mohamed El Gazzar
Journal:  Infect Immun       Date:  2011-12-05       Impact factor: 3.441

3.  Endotoxaemia and serum tumour necrosis factor as prognostic markers in severe acute pancreatitis.

Authors:  A R Exley; T Leese; M P Holliday; R A Swann; J Cohen
Journal:  Gut       Date:  1992-08       Impact factor: 23.059

4.  Glucocorticoid-induced keratinocyte-derived interleukin-1 receptor antagonist(s).

Authors:  S Stosić-Grujicić; M L Lukić
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

Review 5.  Cytokines as biological response modifiers.

Authors:  R C Rees
Journal:  J Clin Pathol       Date:  1992-02       Impact factor: 3.411

6.  IL-1 mediates pulmonary and systemic inflammatory responses to chorioamnionitis induced by lipopolysaccharide.

Authors:  Suhas G Kallapur; Ilias Nitsos; Timothy J M Moss; Graeme R Polglase; J Jane Pillow; Fook-Choe Cheah; Boris W Kramer; John P Newnham; Machiko Ikegami; Alan H Jobe
Journal:  Am J Respir Crit Care Med       Date:  2009-02-20       Impact factor: 21.405

7.  IL-4 down-regulates IL-2-, IL-3-, and GM-CSF-induced cytokine gene expression in peripheral blood monocytes.

Authors:  F H Cluitmans; B H Esendam; J E Landegent; R Willemze; J H Falkenburg
Journal:  Ann Hematol       Date:  1994-06       Impact factor: 3.673

8.  Glomerular expression of interleukin-1 receptor antagonist and interleukin-1 beta genes in antibody-mediated glomerulonephritis.

Authors:  F W Tam; J Smith; S J Cashman; Y Wang; E M Thompson; A J Rees
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

9.  Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance.

Authors:  D J Berg; R Kühn; K Rajewsky; W Müller; S Menon; N Davidson; G Grünig; D Rennick
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

10.  Endogenously opsonized particles divert prostanoid action from lethal to protective in models of experimental endotoxemia.

Authors:  D F Eierman; M Yagami; S M Erme; S R Minchey; P A Harmon; K J Pratt; A S Janoff
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.